Prediction: The Trump Bull Market Is About to End -- but These Stocks Will Rise Anyway

PPI rose 3.4% YoY and Q4 2025 GDP slowed to 1.4% while U.S. payrolls fell by 92,000 in February, and a U.S./Israel attack on Iran with potential Strait of Hormuz disruption raises the risk of oil-driven inflation. Valuations are strained (Shiller CAPE near its second-highest since 2000), leaving the Fed torn between fighting inflation and supporting jobs. Defensive picks highlighted: Berkshire Hathaway (large cash buffer, diversified insurance/utilities), Enbridge (5.2% yield, 31-year dividend growth, pipeline/utility exposure), and Vertex Pharmaceuticals (CF franchise, potential accelerated approval filing H1 2026 and pivotal kidney drug data by year-end).

Analysis

The geopolitical shock that underlies the recent market repricing has an outsized pathway into global inflation via transport and insurance channels rather than only crude spot prices. Rerouting, longer sailing times, and higher war-risk premia typically add 30–70bps to finished-goods inflation within 3–6 months and create uneven input-cost spikes that show up first in wholesale measures and later in consumer services.

That transmission favors businesses with contracted, volume‑insensitive cashflows and penalizes high‑duration growth multiple companies whose valuations are driven by cashflows beyond the 3‑5 year horizon. Midstream and regulated-utility style businesses tend to convert elevated commodity price volatility into stable distributable cash if their tariff structures are insulated from spot swings, while pure-play tech and long-dated biotech optionality compress as the term premium rises.

Company-level secondaries matter: capital-rich conglomerates face both optionality and governance risk — the former from cheap asset buys in stress, the latter from pressure to deploy float into cyclicals at inopportune prices. Biotech names remain binary: positive regulatory or phase‑III outcomes can re-rate shares dramatically, but negative reads often erase near-term market value, making volatility-managed option structures preferable.

Given the macro/monetary crosswinds, the most robust portfolios will mix defensive income with event-driven optionality and a disciplined tail-hedge. Position sizing should reflect a higher probability of multiple compression over the next 6–12 months, with concentrated upside kept in vehicles that can be realized or hedged on clinical/regulatory timelines rather than broad market beta.

Key Decisions for Investors

• Relative-value ballast: Buy BRK.B (BRKB) equal-weight position sized to 1–2% of portfolio and short 50% notional of that beta via S&P futures (3–9 month horizon). Rationale: preserves upside optionality from opportunistic capital deployment while materially reducing drawdown exposure; expect protection cost ~200–400bps of position per quarter depending on futures funding.
• Inflation-resilient income play: Initiate a 6–18 month overweight in ENB funded by trimming cyclical industrial exposure (XLI) by a similar notional. Hedge rate sensitivity by buying 12-month put protection on ENB or selling covered calls to finance downside protection; target asymmetry: 10–15% upside potential vs limited 6–8% funded downside.
• Event-option for concentration upside: Use an 12–24 month call calendar on VRTX (buy longer-dated calls, sell nearer-dated calls) ahead of regulatory/trial catalysts. Risk = premium paid; reward = multi-bagger if pivotal readouts/approval occur. Cap initial allocation to <1% NAV given binary tail risk.
• Tail hedge against systemic derate: Buy a 3–6 month S&P put spread (e.g., 10–20% OTM strikes) sized to protect 5–10% of NAV or, alternatively, buy VIX call calendar for discretionary protection. Accept ongoing premium as insurance; triggers: sustained oil-price inflection or a surprise Fed hike.
• Contrarian pair (rotate duration): Long BRK.B / short NVDA (equal notional, rebalanced monthly) over 6–12 months to trade likely multiple compression in long-duration tech vs capital‑deployment optionality. Risk: NVDA outperformance driven by another AI catalyst; cap by using collars on the long leg.